Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Research Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK) on Bullrun: market cap HKD 3.62B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker3378.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 3.62B
- Financial periodFY2025
- RevenueCNY 0
- Net income-CNY 131.01M
- Free cash flow-CNY 104.32M
Valuation Snapshot
latest market cap is HKD 3.62B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 0 | -CNY 131.01M | -CNY 104.32M | n/a | -1.11 | CNY 614.40M | CNY 55.86M | CNY 697.74M |
| FY2024 | CNY 0 | -CNY 115.83M | -CNY 111.10M | n/a | -0.85 | CNY 161.21M | CNY 11.83M | CNY 166.24M |
| FY2023 | CNY 0 | -CNY 76.06M | -CNY 56.78M | n/a | -0.56 | CNY 162.50M | CNY 15.03M | CNY 268.13M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 3.62B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hanx Biopharmaceuticals (Wuhan) Co., Ltd.'s market cap?
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.'s market capitalization is HKD 3.62B.
What does Hanx Biopharmaceuticals (Wuhan) Co., Ltd. do?
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. engages in the research and development of immune-oncology therapies. The company's product pipeline includes HX009, a bifunctional anti-PD-1/SIRPa fusion protein that is in Phase IIa clinical trials for the treatment of EBV+ non-Hodgkin lymphoma, acral/mucosal subtype melanoma, relapsed/refractory melanoma post-PD-1 therapy, and Biliary tract cancer; HX044, a CTLA-4/SIRPa bifunctional fusion protein which is in Phase Ia for the treatment of solid tumours; HX301, a novel oral multi-kinase inhibitor that is in Phase IIa for the treatment of.